Indaptus Therapeutics (INDP) Cash from Financing Activities (2020 - 2025)

Indaptus Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $2.2 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities fell 13.76% year-over-year to $2.2 million; the TTM figure through Sep 2025 stood at $13.5 million (up 307.16% YoY), while the FY2024 annual figure was $4.7 million, changed N/A from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $2.2 million, down from $6.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $42.5 million in Q3 2021, with the low at $38064.0 in Q2 2024.
• The 3-year median for Cash from Financing Activities is $2.2 million (2025), against an average of $5.9 million.
• The sharpest annual moves came in 2021 and 2025: Cash from Financing Activities tumbled 60.48% in 2021, then surged 16411.32% in 2025.
• Indaptus Therapeutics' Cash from Financing Activities stood at $363058.0 in 2021, then jumped by 396.29% to $1.8 million in 2024, then rose by 24.06% to $2.2 million in 2025.
• Business Quant data shows INDP's Cash from Financing Activities at $2.2 million in Q3 2025, $6.3 million in Q2 2025, and $3.2 million in Q1 2025.